{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002892","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.669473+00:00","generated_at":"2026-06-07T03:18:30.486967+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share","bullets":["Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.","Underwriters have 30-day option for up to 2,572,500 additional shares; if exercised, net ~$323.9M.","Proceeds plus existing cash expected to fund operations through 2025.","Offering led by Morgan Stanley, J.P. Morgan, Jefferies, Stifel; expected to close January 9, 2024.","Shares sold by Dyne; no selling stockholders participating."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002892","json":"https://secwatch.observer/filing/0001193125-24-002892.json","markdown":"https://secwatch.observer/filing/0001193125-24-002892.md","text":"https://secwatch.observer/filing/0001193125-24-002892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/0001193125-24-002892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/d110504d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:18:30.486967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}